In periodontitis, levels of inflammatory cytokine IL-1 are high and correlate with disease severity, while levels of anti-inflammatory IL-4 are low or undetectable and decreasing levels of IL-4 correlate with increasing severity. IL-1 contributes to loss of attachment and alveolar bone destruction by increasing expression of matrix metalloproteinases. MMP-3 has broad substrate specificity and can activate other pro-MMP. It is found in increased levels in diseased sites, and levels are correlated with severity and progression. Previous studies identified the SIRE site (stromelysin IL-1 responsive element) as a repressor element involved in suppressing the IL-1 induction of MMP-3. Others also identified this site as a common 5T/6T polymorphism, with the 6T site being a more effective repressor element. Genotype at this site has been linked to tissue levels of MMP-3 and to susceptibility or severity of a number of diseases. In cardiovascular disease (a condition associated with periodontitis), homozygosity for the higher-expressing 5T allele is associated with myocardial infarction and aneurysm, while the lower-expressing 6T allele is associated with atherosclerosis. It is therefore clear that regulation of this gene must be tightly controlled to maintain correct tissue homeostasis, and that understanding these control mechanisms is important for a variety of pathologies. We recently found that proteins binding to the SIRE site include NF-kappaB p50 and p65 and ZBP-89. We also recently showed that IL-1 induction of MMP-3 is suppressed by IL-4 in human gingival fibroblasts isolated from patients with periodontitis.
The Specific Aims of this application are to: 1) study the roles of transcription factors interacting with the polymorphic SIRE site in the MMP-3 promoter, and 2) determine the mechanism of suppression of MMP-3 expression by IL-4. In doing so, we hope to gain information about complex gene regulatory mechanisms involved in MMP-3 regulation, but also continue to contribute to the research environment at PCOM and to the training of its students in research in general, and molecular biology in particular.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15DE016277-01
Application #
6848196
Study Section
Oral, Dental and Craniofacial Sciences Study Section (ODCS)
Program Officer
Lumelsky, Nadya L
Project Start
2004-09-28
Project End
2007-08-31
Budget Start
2004-09-28
Budget End
2007-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$218,250
Indirect Cost
Name
Philadelphia College of Osteopathic Med
Department
Biochemistry
Type
Schools of Osteopathy
DUNS #
075490854
City
Philadelphia
State
PA
Country
United States
Zip Code
19131
Chambers, Mariah; Kirkpatrick, Garrett; Evans, Michel et al. (2013) IL-4 inhibition of IL-1 induced Matrix metalloproteinase-3 (MMP-3) expression in human fibroblasts involves decreased AP-1 activation via negative crosstalk involving of Jun N-terminal kinase (JNK). Exp Cell Res 319:1398-408
Borghaei, Ruth C; Chambers, Mariah (2009) Expression of transcription factor zinc-binding protein-89 (ZBP-89) is inhibited by inflammatory cytokines. Pathol Lab Med Int 1:7-12
Borghaei, Ruth C; Gorski, Grzegorz; Javadi, Masoud et al. (2009) NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter. Biochem Biophys Res Commun 382:269-73
Stewart, Denise; Javadi, Masoud; Chambers, Mariah et al. (2007) Interleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARgamma activation in human gingival fibroblasts. BMC Mol Biol 8:12
Borghaei, Ruth C; Rawlings Jr, P Lyle; Javadi, Masoud et al. (2004) NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. Biochem Biophys Res Commun 316:182-8
Jenkins, Kosunique; Javadi, Masoud; Borghaei, Ruth Carter (2004) Interleukin-4 suppresses IL-1-induced expression of matrix metalloproteinase-3 in human gingival fibroblasts. J Periodontol 75:283-91